Prestige Biopharma Opening Of Global-scale Vaccine Centre In South Korea

KUALA LUMPUR, Dec 1 -- Prestige BioPharma Limited, a Singapore-based biopharmaceutical with operations in the USA and South Korea, is pleased to announce the grand opening of its global-scale Vaccine Center in Osong, South Korea.

The opening ceremony was held on Dec 1, at the Vaccine Center in Osong Campus.

The ceremony was attended by many distinguished guests including Minister for Government Policy Coordination Yun-cheol Koo, Deputy Governor Il-hong Seong of Chungbuk Province, Mayor of Cheongju City Beom-deok Han, Representatives from Octava Fund Limited Joseph Tey and Sze Khai Pang.

PBP commenced construction of its Vaccine Center in April and completed the global-scale manufacturing facility with a total area of 10,342.88 m2 and a total capacity of 104,000 litres (52 units of 2,000 liter bioreactors) in only eight months by employing Prestige Biologics proprietary engineering technology, ALITA Smart BioFactoryTM.

With the ALITA system which provides combined advantages of Stainless Steel & Single-Use system, different types of vaccines can be produced in versatile custom manufacturing suites. The Vaccine Center’s Single-Use bioreactors also enhance operational efficiency and productivity while minimising the risk of cross contamination.

PBP is currently focusing on two COVID-19 vaccine projects to produce Sputink V and Sputink Light vaccines. PBP’s global-scale Vaccine Center is capable of producing around 2.6 billion doses of the first dose of Sputnik V vaccine (Ad26 adenovirus vector) per year.

The centre will soon be prepared to produce other types of vaccines including mRNA vaccines to actively respond to the growing demands of COVID-19 vaccines.

The company ultimately aims to develop its own vaccine products to combat potential future pandemics and PBP Vaccine Center will be the basecamp for this journey.

In a statement, PBP CEO, Dr Lisa S. Park said: “We are very pleased to complete the Prestige Biopharma Vaccine Center as planned this year with our Group’s unique and unmatched engineering technology, ALITA Smart BioFactory” and “this Vaccine Center will be playing a significant role in our fight against Covid-19 and possible future pandemics”.

-- BERNAMA